RxDoctor Payments Data

George Morris, MD

Epilepsy · Milwaukee, WINPI 1295778629

Payments from drug & device makers

$78,175in general payments, 2019–2025

Across 108 payments — averaging $723.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Livanova USA, Inc.$51K
  • UCB SA$17K
  • UCB, Inc.$8K
  • Eisai Inc.$2K
  • AbbVie$340
  • Vertex$315
  • plus $742 from 9 others

What the payments were for

  • Consulting fees$5,41539%
  • Speaking & faculty fees$7,17552%
  • Food & beverage$1,1869%
  • Education$170%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few epilepsy providers in Wisconsinto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$42,820
Medicare patients
243
Services billed
506

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EpidiolexCannabidiol (Cbd)130$876,327
BriviactBrivaracetam193$576,897
FinteplaFenfluramine Hcl28$430,355
XcopriCenobamate227$374,487
FycompaPerampanel172$247,884
VimpatLacosamide98$191,651
AptiomEslicarbazepine Acetate55$181,986
FelbatolFelbamate16$74,269
Oxtellar XrOxcarbazepine22$66,849
Lacosamide538$66,656
KeppraLevetiracetam30$65,051
OnfiClobazam12$50,461
Tiagabine Hcl35$33,401
Felbamate64$32,068
ValtocoDiazepam38$29,718

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Briviact, Fintepla, Vimpat, Nayzilam$7,570$1,227,306357 claims
SK Life Science, Inc.Xcopri$45$374,487227 claims
Eisai Inc.Fycompa$1,879$247,884172 claims
Sunovion Pharmaceuticals Inc.Aptiom$13$181,98655 claims
Supernus Pharmaceuticals, Inc.Oxtellar Xr$112$66,84922 claims
UCB SAKeppra$16,649$65,05130 claims
Neurelis, Inc.Valtoco$11$29,71838 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few epilepsy providers in Wisconsinon file to place this against a meaningful peer group, so we don't.

Other epilepsy in Milwaukee

Where these figures come from

Is this you, or does something look wrong? →